Since those human tumor cell lines with EGFR/ErbB2-overexpressing are more sensitive to lapatinib cytotoxicity, according to our study, lapatinib blocks growth signals mediated by either important EGFR/ErbB2 signaling through moderate amounts of EGFR and ErbB2 receptors or unveiled targets associated with HCC proliferation. This evidence concerns the gene ERBB2 and neoplasm.